Pages that link to "Q37348458"

The following pages link to Adenosine A2A receptor antagonist istradefylline reduces daily OFF time in Parkinson's disease (Q37348458):

Displaying 48 items.

• Emerging preclinical pharmacological targets for Parkinson's disease (Q26764724) (← links)
• Therapy for Parkinson's disease: what is in the pipeline? (Q26991826) (← links)
• Striatal adenosine A2A receptor expression is controlled by S-adenosyl-L-methionine-mediated methylation (Q34123200) (← links)
• New treatments for the motor symptoms of Parkinson's disease (Q34443682) (← links)
• Recent advances in treating Parkinson's disease (Q34554401) (← links)
• Automated reference region extraction and population-based input function for brain [(11)C]TMSX PET image analyses (Q34957647) (← links)
• Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline? (Q37506507) (← links)
• Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems (Q38123275) (← links)
• Non-dopaminergic treatments for motor control in Parkinson's disease (Q38126817) (← links)
• Treatment of motor fluctuations in Parkinson's disease: recent developments and future directions. (Q38170421) (← links)
• Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant (Q38199744) (← links)
• Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued (Q38200930) (← links)
• Advances in non-dopaminergic treatments for Parkinson's disease (Q38218083) (← links)
• Efficacy of adenosine A2A receptor antagonist istradefylline as augmentation for Parkinson's disease: a meta-analysis of randomized controlled trials (Q38237288) (← links)
• Emerging drugs for levodopa-induced dyskinesia (Q38242091) (← links)
• Pharmacological strategies for the management of levodopa-induced dyskinesia in patients with Parkinson's disease (Q38262418) (← links)
• History and perspectives of A2A adenosine receptor antagonists as potential therapeutic agents (Q38395423) (← links)
• Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future (Q38478999) (← links)
• New treatments for levodopa-induced motor complications (Q38570434) (← links)
• Current Nondopaminergic Therapeutic Options for Motor Symptoms of Parkinson's Disease (Q38658203) (← links)
• New and emerging medical therapies in Parkinson's disease (Q38718194) (← links)
• Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia (Q38811387) (← links)
• Nondopaminergic treatments for Parkinson's disease: current and future prospects (Q38845546) (← links)
• How does adenosine control neuronal dysfunction and neurodegeneration? (Q38882782) (← links)
• Prevalence and treatment of LUTS in patients with Parkinson disease or multiple system atrophy (Q39037307) (← links)
• Motor complications in an incident Parkinson's disease cohort (Q40836037) (← links)
• Levodopa-induced Dyskinesia: Clinical Features, Pathophysiology, and Medical Management (Q41626118) (← links)
• Targeting Adenosine Signaling in Parkinson's Disease: From Pharmacological to Non-pharmacological Approaches (Q47137101) (← links)
• The effect of istradefylline for Parkinson's disease: A meta-analysis (Q47138950) (← links)
• Effects of Rifampin on the Pharmacokinetics of a Single Dose of Istradefylline in Healthy Subjects (Q48020769) (← links)
• Istradefylline for Restless Legs Syndrome Associated with Parkinson's Disease (Q49388393) (← links)
• Motor Complications of Dopaminergic Medications in Parkinson's Disease. (Q55279095) (← links)
• Adenosine A2A Receptor Antagonists in Neurodegenerative Diseases: Huge Potential and Huge Challenges. (Q55297865) (← links)
• Treatment of advanced Parkinson's disease. (Q55645561) (← links)
• Adenosine A2A Receptors: Localization and Function (Q57778947) (← links)
• Long-term safety and efficacy of adjunctive rasagiline in levodopa-treated Japanese patients with Parkinson's disease (Q64298270) (← links)
• Biomarker repurposing: Therapeutic drug monitoring of serum theophylline offers a potential diagnostic biomarker of Parkinson's disease (Q64864682) (← links)
• The factors associated with impulse control behaviors in Parkinson's disease: A 2-year longitudinal retrospective cohort study (Q64866218) (← links)
• Adenosine A2A receptor antagonists in Parkinson's disease: still in the running (Q87375245) (← links)
• Cyclic AMP-producing chemogenetic activation of indirect pathway striatal projection neurons and the downstream effects on the globus pallidus and subthalamic nucleus in freely moving mice (Q87945516) (← links)
• From medications to surgery: advances in the treatment of motor complications in Parkinson's disease (Q90087446) (← links)
• Effect of caffeine on long-term potentiation-like effects induced by quadripulse transcranial magnetic stimulation (Q90395840) (← links)
• Microbiota and Other Preventive Strategies and Non-genetic Risk Factors in Parkinson's Disease (Q90745434) (← links)
• On the Role of Adenosine A2A Receptor Gene Transcriptional Regulation in Parkinson's Disease (Q92237519) (← links)
• Pharmacological Insights into Levodopa-induced Motor Fluctuations in Patients with Parkinson's Disease (Q92583731) (← links)
• Adenosine 2A Receptor Antagonists for the Treatment of Motor Symptoms in Parkinson's Disease (Q92583755) (← links)
• Potentiation of cannabinoid signaling in microglia by adenosine A2A receptor antagonists (Q92719134) (← links)
• A Stage-Based Approach to Therapy in Parkinson's Disease (Q92753479) (← links)